Serodiagnosis of Trichomonas vaginalis infection by the indirect fluorescent antibody test.

Mason, Peter R.

doi:10.1136/jcp.32.12.1211

Cited by 40 publications

(30 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Very little is also known about the serologic response to T. vaginalis infection. In studies conducted to date, serum antitrichomonad antibodies have been observed in male and female patients with current trichomonosis (14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27), and in those with a documented history of trichomonosis months to years previously (16,21). Although not specifically investigated for T. vaginalis, the response to other genital, mucosal infections (e.g., Chlamydia trachomatis infection) is frequently stronger in those with chronic rather than acute infections (28).…”

Section: Discussionmentioning

confidence: 99%

Plasma Antibodies against Trichomonas vaginalis and Subsequent Risk of Prostate Cancer

Sutcliffe

Giovannucci

Alderete

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

168

217

View full text Add to dashboard Cite

Background: Although several previous case-control studies have investigated associations between sexually transmitted infections (STI) and prostate cancer, most have focused on gonorrhea and syphilis, two well-recognized, symptomatic STIs. Another STI of interest for prostate carcinogenesis is trichomonosis, a less well recognized and frequently asymptomatic STI with known prostate involvement. We investigated this infection in relation to incident prostate cancer in a nested case-control study within the Health Professionals Follow-up Study. Methods: Prostate cancer cases were men diagnosed with prostate cancer between the date of blood draw (1993)(1994)(1995) and 2000 (n = 691). Controls were men who had had at least one prostate-specific antigen test and who were free of prostate cancer and alive at the time of case diagnosis. One control was individually matched to each case by age (n = 691). Serologic evidence of a history of trichomonosis was as-

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma Antibodies against Trichomonas vaginalis and Subsequent Risk of Prostate Cancer

Sutcliffe

Giovannucci

Alderete

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

168

217

View full text Add to dashboard Cite

show abstract

“…The antibody response to T. vaginalis infection is well documented and includes circulating serum and cervicovaginal immunoglobulin A (IgA), IgG, and IgM (8,19,83,113,114,118,119). However, these antibodies appear to provide only limited protection from invading parasites, and antibody titers progressively dwindle after infection is eradicated by treatment (44).…”

Section: Vaccinesmentioning

confidence: 99%

Treatment of Infections Caused by Metronidazole-ResistantTrichomonas vaginalis

et al. 2004

View full text Add to dashboard Cite

Infections with the sexually transmitted protozoan Trichomonas vaginalis are usually treated with metronidazole, a 5-nitroimidazole drug derived from the antibiotic azomycin. Metronidazole treatment is generally efficient in eliminating T. vaginalis infection and has a low risk of serious side effects. However, studies have shown that at least 5% of clinical cases of trichomoniasis are caused by parasites resistant to the drug. The lack of approved alternative therapies for T. vaginalis treatment means that higher and sometimes toxic doses of metronidazole are the only option for patients with resistant disease. Clearly, studies of the treatment and prevention of refractory trichomoniasis are essential. This review describes the mechanisms of metronidazole resistance in T. vaginalis and provides a summary of trichomonicidal and vaccine candidate drugs

show abstract

“…Other STIs such as chancroid, non-gonococcal urethritis, pelvic inflammatory disease (PID), genital herpes, candidiasis and trichomoniasis have also been found to be a problem in Zimbabwe. For instance, a prevalence of trichomoniasis in Zimbabwe was estimated at 26 percent (Mason, 1978). In yet another study, Mason et a l, (1983) isolated Trichomonas vaginalis in 31 percent of 199 pregnant women and 37 percent of STI patients attending a local clinic.…”

Section: Introductionmentioning

confidence: 99%

A survey on contact tracing of sexually transmitted infections in Mazowe district (Zimbabwe)

Chibatamoto¹,

Charimari²,

Chando³

2000

Jassa

View full text Add to dashboard Cite

Serodiagnosis of Trichomonas vaginalis infection by the indirect fluorescent antibody test.

Cited by 40 publications

References 9 publications

Plasma Antibodies against Trichomonas vaginalis and Subsequent Risk of Prostate Cancer

Plasma Antibodies against Trichomonas vaginalis and Subsequent Risk of Prostate Cancer

Treatment of Infections Caused by Metronidazole-ResistantTrichomonas vaginalis

A survey on contact tracing of sexually transmitted infections in Mazowe district (Zimbabwe)

Contact Info

Product

Resources

About